DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tegaserod
Tegaserod
THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders
Tegaserod in the Treatment of Constipation-Predominant Functional Gastrointestinal Disorders
Zelnorm®) for Safety Reasons
Zelnorm Page: 1 of 5
Rifaximin (XIFAXAN)
Emerging Drug List — Tegaserod Hydrogen Maleate
Zelnorm Fda Ac Backgrounder Errata
Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
I NDA/BLA Multi-Disciplinary Review and Evaluation
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
A Brief Summary for 5-HT Receptors
ZELNORM™ (Tegaserod Maleate) for the Treatment of Irritable Bowel
Neurohumoral Control of Gastrointestinal Motility
Contents Encourage the Integration of Pharmacovigilance for Regulatory Matters Antiretrovirals in Some Sub-Saharan African Countries
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects Of
Involvement of CB1 Receptors and Fatty Acid Amide Hydrolase
Top View
Therapeutic Drug Guidelines for ATCS
Drugs/Medications Known to Cause Hyperhidrosis Certain Prescriptions
Theoretical Study of the Interaction of Agonists with the 5-HT2A Receptor
Australian Adverse Drug Reactions Bulletin, Feb 2003
Meta-Analysis: the Treatment of Irritable Bowel Syndrome
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission
Emerging Drug List TEGASEROD
5-HT Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders
New Pharmaceutical Approaches to the Treatment of IBS: Future Development & Research
Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist S
Tegaserod Inhibits Noxious Rectal Distention Induced Responses and Limbic System C-Fos Expression in Rats with Visceral Hypersensitivity
PROGRAM NEWS SUPPORT Act Requirements FALL 2019 Implemented October 1, 2019
FDA Introductory Remarks Gastrointestinal Drugs Advisory Committee
WO 2009/092994 Al
(12) Patent Application Publication (10) Pub. No.: US 2014/0166027 A1 FUSZ Et Al
Irritable Bowel Syndrome (IBS): Introduction
Therapeutic Drug Class
WO 2009/141572 Al
NYS Medicaid Fee-For-Service Preferred Drug List PREFERRED DRUG LIST – TABLE of CONTENTS I
A Review of the Role of Melatonin in Irritable Bowel Syndrome
September 2019 DUR Board Meeting Minutes
Zelnorm® (Tegaserod Maleate)
5-HT Receptors and Their Ligands, Tocris Reviews No
Drug Benefit Guide
Print This Article
Irritable Bowel Syndrome: Minimize Testing, Let Symptoms Guide Treatment
Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome (IBS): an Overview
Medical Necessity Criteria for Pharmacy Edits, 5.01.605
IBS-Monograph-2018.Pdf
The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
Simple Spectrophotometric Determination of Tegaserod Maleate in Pharmaceutical Dosage Forms
Risk Assessment and Risk Mitigation Review(S)
5-Step Plan to Treat Constipation in Psychiatric Patients
Irritable Bowel Syndrome and Constipation Agents
Effects of Novel TRPA1 Receptor Agonist ASP7663 in Models of Drug-Induced Constipation and Visceral Pain
W O 2014/093127 a 2 19 June 2014 (19.06.2014) W P O P C T
What Is the Role of Prokinetic Agents for Constipation?
Functional Gastrointestinal Disorders
AHFS Pharmacologic-Therapeutic Classification System
Serotonergic Modulation of Visceral Sensation: Lower Gut M Camilleri
Large Group Tier 4 HMO and PPO Prescription Drug List DMHC Version
Prior Authorization — Premium
Tegaserod (Zelnorm)
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Treatment of Irritable Bowel Syndrome SUSAN K
ZELNORM™ Safely and Effectively
Neuropharmacology of 5-Hydroxytryptamine
Prucalopride for Gastrointestinal Motility Disorders: a Review of Clinical Effectiveness
Prucalopride for the Treatment of Chronic Idiopathic Constipation in Adults
Zelnorm (Tegaserod), for the Treatment of Adult Women Less Than 65 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Tegaserod (Zelnorm®) EOCCO POLICY
Clinical Endocannabinoid Deficiency
Zelnorm) Reference Number: CP.PMN.206 Effective Date: 05.14.19 Last Review Date: 08.20 Revision Log Line of Business: Commercial, Medicaid
FDA Briefing Document Gastrointestinal Drug Advisory Committee Meeting